

Listing of Claims:

1-92 (cancelled).

93 (new). A lipoprotein compound delivery particle, comprising:

- (a) from 0.1 to 90 percent by weight of a lipophilic compound to be delivered;
- (b) from 0 to 50 percent by weight of at least one polar lipid in an amount sufficient to form a particle with said lipophilic compound
- (c) from 0 to 90 percent by weight of at least one neutral lipid; and
- (d) from .5 to 90 percent by weight of a truncated apolipoprotein B protein in said particle having a deleted LDL receptor binding region.

94 (new). The particle according to claim 93, wherein said apolipoprotein B further comprises a fused heterologous moiety, where said heterologous moiety is a member of a specific binding pair.

95 (new). The particle according to claim 94, wherein said heterologous moiety is a peptide.

96 (new). The particle according to claim 94, wherein said heterologous moiety is an antibody.

97 (new). The particle according to claim 94, wherein said heterologous moiety is a single chain antibody.

98 (new). The particle according to claim 94, wherein said heterologous moiety is a single chain anti HER2 antibody.

99 (new). The particle according to claim 93, wherein said particle has a diameter less than 18 nanometers.

100 (new). The particle according to claim 93, wherein said particle has a diameter of from 5 to 5,000 nanometers.

101 (new). The particle according to claim 93, wherein said said apolipoprotein B is selected from the group consisting of through apoB74.

102 (new). The particle according to claim 93, wherein said particle has a neutral core, and wherein said ApoB comprises at least ApoB 19.5.

103 (new). The particle according to claim 93, wherein said apolipoprotein B is mature Apo B.

104 (new). The particle according to claim 93, wherein said apolipoprotein B is mammalian Apo B.

105 (new). The particle according to claim 93, wherein said apolipoprotein B is human Apo B.

106 (new). The particle according to claim 93, wherein said at least one polar lipid is a phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, glycosphingolipid, lysolipid thereof, or combinations thereof.

107 (new). The particle according to claim 93, wherein wherein said at least one neutral lipid comprises a triglyceride, cholesterol, derivative thereof, or combination thereof.

108 (new). The particle according to claim 93, wherein said compound to be delivered is paclitaxel.

109 (new). The particle according to claim 93, comprising:

- (a) from 0.1 to 50 percent by weight of said compound to be delivered;
- (b) from 10 to 50 percent by weight of said at least one polar lipid;
- (c) from 0 to 10 percent by weight of at said least one neutral lipid; and
- (d) from 50 to 90 percent by weight of said truncated apoB.

110 (new). The particle according to claim 109, wherein said particle is a discoidal particle.

111 (new). The particle according to claim 93, comprising:

- (a) from 0.1 to 55 percent by weight of said compound to be delivered;
- (b) from 15 to 55 percent by weight of said at least one polar lipid;
- (c) from 2 to 30 percent by weight of at said least one neutral lipid; and
- (d) from 30 to 80 percent by weight of said truncated apoB.

112 (new). The particle according to claim 111, wherein said particle is a small emulsion particle.

113 (new). The particle according to claim 111, comprising:

- (a) from 0.1 to 80 percent by weight of said compound to be delivered;
- (b) from 1 to 30 percent by weight of said at least one polar lipid;
- (c) from 30 to 90 percent by weight of at said least one neutral lipid; and
- (d) from .5 to 10 percent by weight of said truncated apoB.

114 (new). The particle according to claim 113, wherein said particle is a large emulsion particle.